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Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have been
under investigation for the treatment of autoimmune diseases. To model the mecha-
nism of action of these anti-human CD3 mAbs in the murine system, an Fc-modified
anti-mouse CD3 antibody (N297A) was generated. N297A exhibited similar biological
effects as Fc-modified anti-human CD3 antibodies including rapid, reversible reduction
in peripheral leukocyte numbers, differential modulation of activated versus resting
T cells, and reduced levels of induced cytokine release compared to the non-Fc-modified
parent antibody. In an in vivo model of colitis induced by adoptive transfer of IL–
10-deficient cells, administration of N297A significantly reduced body weight loss.
As N297A shared many functional characteristics of non-FcR binding anti-human
CD3 mAbs both in vitro and in vivo, it provides a means to model the mechanisms
of action of Fc-modified anti-human CD3 antibodies in mouse.
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INTRODUCTION
In 1986, the murine anti-human CD3ε monoclonal antibody (mAb), OKT3
(muromonab-CD3), was approved for the treatment of steroid-resistant renal
transplantation rejection (Thistlethwaite et al., 1988). OKT3 proved to be a
strong immunosuppressive agent due to its broad reactivity with all T cells.
However, the induction of both human anti-mouse antibodies to OKT3 and
severe cytokine release syndrome (CRS) resulting from the potent agonistic
activity of this mAb have limited its use (Gleixner et al., 1991; Sgro, 1995;
Thistlethwaite et al., 1988).
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Attempts to produce anti-human CD3 mAbs without the side effects of
OKT3 have generated mAbs with improved tolerability and safety character-
istics (Carpenter et al., 2002; Cole et al., 1999; Norman et al., 2000). A
common feature of these improved mAbs is the reduction of the murine amino
acids with those commonly found in human immunoglobulins (humanization),
reducing the level of immunogenicity. The second common feature of these
antibodies is the modification of the Fc portion of the antibodies to reduce FcR
binding and therefore reduce side effects associated with cross-linking of CD3
via an Fc-dependent mechanism.
Representatives of this novel class of next generation anti-CD3 antibodies
include visilizumab (HuM291; NUVION®), teplizumab (hOKT3γ1-Ala-Ala),
and ChAglyCD3 (TRX4). Each of these mAbs has been under evaluation in
clinical trials for T cell mediated autoimmune indications including graft versus-
host disease, ulcerative colitis, Crohn’s disease and type I diabetes (Carpenter
et al., 2002; Herold et al., 2003; Keymeulen et al., 2005; Plevy et al., 2007;
Targan S, 2005; Vexler and Woo, 2006; Woodle et al., 1998). The Fc-modified
anti-human CD3 mAbs have shown promise in a number of these trials and
have an improved safety profile, compared to the original OKT3 therapy.
Common adverse events in the recent clinical trials include mild to moderate
flu-like symptoms, rash, and transient symptoms of Epstein-Barr viral
mononucleosis (Carpenter et al., 2002; Keymeulen et al., 2005). The flu-like
symptoms with anti-CD3 therapy are a class phenomenon and attributable to
cytokine release which, although dramatically reduced by the Fc modifica-
tions, still occurs when the anti-CD3 mAbs bind to T cells (Alegre et al., 1991;
Ferran et al., 1990; Vossen et al., 1995). Another common characteristic of
these Fc-modified mAbs is a rapid reduction of peripheral blood lymphocytes
following the initial dosing, which is a useful pharmacodynamic marker for
the mAb activity (Bisikirska et al., 2005; Carpenter et al., 2002; Hommes
et al., 2005; Hsu et al., 1999). However, the relationship of the change in
peripheral blood T cell count and clinical response remains to be elucidated.
Potential mechanisms of action of antibody therapies are often evalu-
ated using animal models of human disease. However, the restricted bind-
ing of the anti-human CD3 mAb to human and chimpanzee has prevented
studies in small animal models as well as in non-human primates. Use of
Fc-modified anti-murine CD3 antibodies that can act as surrogates for their
human counterparts has therefore been crucial for these mechanistic stud-
ies. Important early data came from studies using a hamster anti-mouse
CD3 antibody (145.2C11). Data generated using this mAb allowed a better
understanding of the role/function of the Fc region of anti-CD3 antibodies.
Subsequent studies with F(ab′)2 fragments of 145.2C11 demonstrated that
the Fc receptor binding capacity of the mAb could be dissociated from
efficacy in animal models (Alegre et al., 1995; Yu and Anasetti, 2000; Yu
et al., 2001).78 D. T. Chao et al.
Since the potent mitogenic activity of OKT3 was due in large part to
Fc-dependent interactions that allowed for cross-linking of the CD3 complex,
the fact that efficacy could be retained in animal models with a non-Fc
containing mAb helped pave the way for the anti-human Fc-modified thera-
pies. While the 145.2C11 mAb, and fragments there of, have been invaluable
in furthering our understanding of an anti-CD3 therapeutic approach, issues
with the production of large quantities of pure F(ab′)2 fragments prompted us
to search for an alternative anti-mouse CD3 analogue.
In this study, we detail the generation of an intact, Fc-modified anti-
mouse CD3 mAb (N297A), which shares many of the functional characteris-
tics of the Fc-modified, low mitogenic anti-human CD3 antibodies. In addition,
N297A can alleviate clinical signs of disease in a murine model of colitis.
Together, these in vitro and in vivo data suggest that we have generated an
Fc-modified anti-CD3 mAb surrogate that should prove useful in the further
dissection of potential mechanisms of action of Fc-modified anti-CD3 mAb in
clinical development.
MATERIAL AND METHODS
Generation of an Fc-Modified Anti-Murine CD3 mAb (N297A)
The CDR sequence from hamster anti-mouse CD3 mAb (145.2C11) was
combined with the murine IgG1 backbone to make a chimeric hamster/mouse
mAb, 145.2C11.mIgG1.wt (WT). A variant containing a modified Fc region
was made by an alanine substitution of murine IgG1 heavy chain at amino
acid N297 in the CH2 region using site directed mutagenesis PCR with the
following two primers: 5′ GCAACC CCGGGA GGAGCA GTTCGCCAGCA 3′
and 5′ TATTGC GGGGTC CCAAGG CAGTGC 3′. SP2/0 cells were then
co-transfected with the heavy chain expressing vectors and p145.2C11-mouse
Cl under mycophenolic acid selection.
Positive clones were chosen based on high mouse IgG1 production
detected by ELISA and binding to EΔC cells (mouse T cells expressing CD3ε)
by flow cytometry. An equivalent negative control mAb (NCNS-1) was gener-
ated by replacing the CDR3 variable region of N297A with non-CD3 binding
hamster antibody sequences; this control mAb was confirmed to have lost the
ability to bind to murine CD3ε on EΔC cells.
Fc Receptor Binding Assay
Expression of Fcγ receptors CD16/32 and CD64 on RAW 264.7 mouse mac-
rophage cell line were confirmed by flow cytometry. Both RAW264.7 and 3T12
cell lines were purchased from ATCC (Bethesda, MD). Control mouse IgG2a,
IgG2b (both against VP7 of blue tongue virus; #CRL-1875 and 1877), andSurrogate for Fc-Modified Anti-Human CD3 mAbs 79
IgG1 (anti-TNP mAb; #TIB-191) antibodies were purified from hybridoma cell
lines purchased from ATCC. 5 × 105 cells were mixed with serial dilution of
primary antibody and incubated at 4°C for 20 minutes. Cells were washed
once with phosphate-buffered saline (PBS) and then incubated with 2.5 μg/ml
of APC conjugated goat anti-mouse IgG, F(ab′)2 fragment specific antibody
(Jackson ImmnoResearch, West Grove, PA) at 4°C for 20 minutes. Samples
were washed in PBS and resuspended in 300 μl of FACS buffer and analyzed
by flow cytometer (FACSCalibur, BD, San Jose, CA).
In vitro Cell-Based Assays
For plate bound antibody stimulation, antibodies were diluted in PBS
and loaded in triplicate into 96-well plates. Plates were left overnight at 4°C
or for 1.5 hours at 37°C to ensure coating of antibodies. Plates were washed
twice with PBS, and 2 × 105 cells were loaded per well in 100 μl of T cell
media (RPMI /10% FCS /15 mM HEPES/2 mM L-glutamine /1 mM sodium
pyruvate /50 μΜ 2-mercaptoethanol with penicillin/streptomycin). For solu-
ble antibody stimulation, 2 × 105 cells were seeded per well in 100 μl of T cell
media. Anti-mouse CD3 antibodies were diluted in PBS and then added to
the cells and cultured for 48 hours. Then, 10 μl of the cell proliferation indi-
cator AlamarBlue® (Biosource, Camarillo, CA) were added per well, and
plates were incubated at 37°C in a 5% CO2 incubator for 4 hours. Plates
were read using a 96-well fluorescence plate reader (SpectraMax GeminiXS,
Molecular Devices, Sunnyvale, CA) with excitation at 530 nm and emission
at 590 nm.
For apoptosis assays, spleen cells (2 × 106 /ml in T cell media) were acti-
vated with 1 μg/ml of concanavalin A (Con A) (Sigma, St. Louis, MO) for 96
hours.
Viable leukocytes were recovered using Ficoll-Paque (Amersham
Bioscience, Piscataway, NJ) and resuspended at 2 × 106 cells/ml in T cell
media supplemented with mouse IL-2 (200 U/ml). Antibodies and cells were
incubated for 24 hours at 37°C. Apoptotic cells were then stained using
TACS Annexin V/PI kit (R&D, Minneapolis, MN). Caspase activity was mea-
sured by adding Caspase-Glo® 3/7 Substrate (Promega, Madison, WI) and
incubating at RT for 30 minutes before measuring luminescence (Perkin
Elmer, Waltham, MA).
Animals
IL-10.NOD-deficient mice (stock #004266) were obtained from The
Jackson Laboratory (Bar Harbor, ME) and bred in-house to generate suffi-
cient mice for the experiments. Six-week-old BALB/c and C57/B6 mice were
purchased from Taconics (Germantown, NY); NOD/C.B-17/scid mice (stock
#001303) were from The Jackson Laboratory. Homozygous TCR transgenic80 D. T. Chao et al.
male mice DO11.10 were purchased from Jackson Laboratory (stock
#003303), and bred with BALB/c females to produce heterozygous transgenic
mice that were used for the experiments. Animal studies were performed fol-
lowing the Guidelines for Ethical Conduct in the Care of Use of Animals
with the approval of the PDL BioPharma Institutional Animal Care Use
Committee.
Monitoring of Peripheral Blood and Detection of Cytokines
Samples were run on a hematology analyzer (Hemavet 950, Drew
Scientific, Waterbury, CT) to obtain a complete blood count. Quantification of
blood cell subsets from 50 μl of whole blood was performed using TruCOUNT
assays with the following mAbs: APC anti-CD4, FITC anti-CD8, PE anti-
CD25 and PerCP anti-CD45 (BD BioScience, San Jose, CA). To measure
cytokine and chemokine concentrations in plasma, 30 μl of each plasma
sample was processed using a 22-plex LINCOplex kit (Linco Research, St.
Charles, MO) following the manufacturer’s instructions.
TCR Transgenic Mice Adoptive Transfer
Spleens were harvested from heterozygous DO11.10 TCR transgenic
female mice (8–12 weeks old). Single cell suspensions were prepared and
stimulated with 0.3 μM of OVA peptide for 72 hours in culture. Activation of
CD4+ T cells was verified by CD25 expression. Viable cells were isolated
using Ficoll and transferred intravenously (i.v.) into BALB/c female mice
(2×107 cells per mouse). Then, 24 hours after cell transfer, the mice were
dosed i.v. with mAb. Mice were sacrificed 18 hours after mAb treatment, and
organs were harvested to generate single cell suspensions for flow analysis.
The mAb KJ1–26 was used to identify the proportion of DO11.10 transgenic
CD4+ T cells.
IL-10 KO Adoptive Transfer IBD Model
Spleens were harvested from IL-10.NOD-deficient male mice that were
older than 10 weeks. CD4+ T cells were isolated using the CD4 Dynabeads kit
(Invitrogen, Carlsbad, CA). The magnetic beads were removed from the
isolated cells with DETACHaBEAD®Mouse CD4 prior to injection. CD4+ T cell
purity was checked by FACS and usually exceeded 95%. Two million CD4+ T
cells were injected i.v. into the tail vein of each NOD/CB.17/scid male mouse.
The mice were checked for clinical symptoms, such as ruffled coat and hutched
posture, and weighed 3 times per week. Colons were harvested and fixed in
10% buffered formalin for histology at study termination. Slides were stained
with hematoxylin and eosin for morphological analysis and then reviewed by a
certified veterinary pathologist.Surrogate for Fc-Modified Anti-Human CD3 mAbs 81
RESULTS
Biological Characteristics of N297A in vitro
Several anti-human CD3 antibodies have been engineered to reduce their
binding to Fc gamma (Fcγ) receptors. In order to generate a low-FcγR binding
anti-mouse CD3 antibody similar to the human counterparts, a hamster/
mouse chimeric antibody with an alanine substitution at amino acid 297 in
the CH2 region of mouse IgG1 was made as described above. Since IgG
binding to CD16 (FcγRI) had the highest affinity compared with other Fcγ
receptors, CHO cells were transfected with mouse CD16 and used to analyze
FcγR binding (Ravetch and Bolland, 2001).
As expected, binding of N297A to mouse CD16 expressed on CHO cells
was substantially reduced compared with non-Fc-modified wild-type IgG1
antibody (WT) (secondary mAb only MFI: 8.8; N297A MFI: 13.3; WT MFI:
127.3). In addition, binding to other activating Fcγ receptors was also tested
using RAW 264.7, a mouse macrophage cell line which endogenously
expresses CD16, CD32, and CD64 (FcγRI, IIB, III). Control mouse antibodies
that did not bind to mammalian antigens were used to detect FcγR binding on
RAW cells. Different isotypes of mouse IgG antibodies typically display vari-
ous affinities to Fcγ receptors (Nimmerjahn and Ravetch, 2007). As expected,
mouse IgG2a showed the strongest binding, followed by mouse IgG2b, and
lastly mouse IgG1 (Figure 1A).
Importantly, non-Fc-modified anti-CD3 IgG1 (WT) antibody had similar
binding pattern as the control mouse IgG1 antibody, whereas the mutant
N297A had no detectable FcγR binding. None of the antibodies demonstrated
detectable binding to 3T12, a non-FcγR expressing mouse fibroblast cell line
Figure 1: N297A did not bind to Fc gamma receptors. (A) RAW264.7, a mouse macrophage
cell line which highly expresses Fcγ receptors, and (B) 3T12, a non-Fcγ receptor-expressing
mouse cell line, were used to analyze binding of antibodies. Serial dilution of mouse antibod-
ies IgG2a (), IgG2b (), IgG1 (), WT () and N297A () were incubated with the cells for 20
minutes on ice. After washing, samples were incubated with secondary APC-conjugated
goat anti-mouse IgG, F(ab′)2 fragment specific antibody (2.5 μg/ml) for detection by flow
cytometry.
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(Fig. 1B). In addition, neither WT nor N297A mediated complement fixation
in vitro with purified naïve spleen T cells as targets while an IgG3 variant of
the same antibody was able to fix complement (data not shown). These data
confirmed that the mutant N297A had reduced FcγR binding compared to its
original antibody (WT).
To examine the mitogenic potential of N297A on spleen cells, N297A was
immobilized in the wells or used in soluble form. Plate-bound N297A induced
a similar level of proliferation of murine spleen cells as chimeric
145.2C11.mIgG1.wt (WT) (Figure 2A). However, while WT stimulated
significant proliferation of spleen cells when added in solution, the soluble
N297A mAb was unable to stimulate detectable proliferation in BALB/c
spleen cells (Figure 2B). The inability of soluble N297A to induce proliferation
Figure 2: Soluble N297A did not induce proliferation but induced apoptosis in activated T cells.
Spleen cells from BALB/c mice were incubated with either plate-bound (A) or soluble (B)
mAbs for 48 hours. Proliferation was determined following incubation with alamarBlue. WT (),
N297A (), or mIgG1 isotype control (✧). (C+D) Spleen cells from BALB/c mice were treated
with WT (), N297A (), or NCNS-1 negative control (✧) mAb for 24 hours with either no prior
activation (C) or prior stimulation with Con A for 96 hours (D). Apoptotic cells were then
stained using TACS Annexin V/PI kit. Cells that did not stain for Annexin V or PI were calculated
and shown as % of viable cells. Triplicate samples for each condition were analyzed and
average values are shown in the graphs.
0
10
20
30
40
50
60
70
80
WT
N297A
NCNS-1
D
%
 
o
f
 
V
i
a
b
l
e
 
C
e
l
l
s
10–4 10–3 10–2 10–1 100 101 102
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
WT
N297A
mIgG1
[mAb] µg/ml
10–4 10–3 10–2 10–1 100 101 102
[mAb] µg/ml
10–4 10–3 10–2 10–1 100 101 102
[mAb] µg/ml
[mAb] µg/ml
10
–5 10
–4 10
–3 10
–2 10
–1 10
0 10
1 102
R
e
l
a
t
i
v
e
 
C
e
l
l
 
N
u
m
b
e
r
B
0
10
20
30
40
50
60
70
80
N297A
NCNS-1
WT
C
%
 
o
f
 
V
i
a
b
l
e
 
C
e
l
l
s
1000
2000
3000
4000
5000
6000
7000
WT
N297A
mIgG1
A
R
e
l
a
t
i
v
e
 
C
e
l
l
 
N
u
m
b
e
rSurrogate for Fc-Modified Anti-Human CD3 mAbs 83
was also observed when spleen cells from multiple mouse strains were tested
(C57/B6, DBA/J1 and NOD/Ltj) (data not shown).
It has been reported that anti-human CD3 mAbs induce apoptosis of
activated human T cells in vitro (Carpenter et al., 2000). Thus, we examined
the apoptotic effect of N297A on activated versus resting mouse spleen cells.
Neither the WT nor N297A induced cell death when incubated with resting
spleen cells (Figure 2C). However, both N297A and WT were capable of induc-
ing significant cell death in activated spleen cells to a similar maximum level
(Figure 2D). Whereas WT exhibited a typical dose-response curve, the N297A
variant demonstrated a maximal effect at 100 ng/ml, with higher doses becoming
less effective. This prozone effect has also been observed with Fc-modified
anti-human CD3 antibodies (Carpenter et al., 2000).
To confirm that the cell death induced by N297A was via apoptosis, we
evaluated the activities of caspase 3 and caspase 7 (standard markers of apop-
totic death). Increased caspase activity was indeed observed, with maximal
activity occurring at concentrations of mAb equivalent to those that gave max-
imal killing in the annexin V/PI assay. Again, higher concentrations of N297A
showed a prozone effect (data not shown). Taken together these data indicate
that N297A is a relevant murine surrogate for Fc-modified anti-human CD3
mAbs with respect to its characteristics in vitro.
N297A Treatment Results in the Transient Reduction of Peripheral 
Blood Lymphocytes and Reduced Cytokine Release in vivo
Treatment of patients with Fc-modified anti-CD3 mAbs leads to a tran-
sient decrease in blood leukocyte counts (Norman et al., 2000). To determine if
this decrease in peripheral blood cells was also mirrored in mice treated with
N297A, mice were dosed either with N297A or control antibodies and bled at
various times thereafter. Hemavet and TruCOUNT analyses were used to
follow general blood cell populations as well as specific subpopulations of T
cells (CD4+ and CD8+ subsets). A reduction in the number of blood lympho-
cytes was detected in samples from both WT and N297A (10 μg/mouse) treated
BALB/c mice as early as 30 minutes post-i.v. injection (Figure 3A). The blood
lymphocytes counts remained low for 24 hours. Both WT- and N297A-induced
blood lymphocyte reduction were also consistently observed in other strains of
mice, including C57/B6, DAB/J, CD-1 and SJL (data not shown). The
reduction of T cells associated with N297A treatment was transient as has
been observed in humans treated with Fc-modified anti-CD3 mAb. Both CD4+
and CD8+ peripheral T cell numbers returned to baseline within 6 days
(Figure 3B).
Even with modifications of the FcγR binding regions of humanized anti-
human CD3 mAb, elevated serum cytokine levels have still been observed
after the initial dose (Herold et al., 2003; Keymeulen et al., 2005; Norman et al.,84 D. T. Chao et al.
2000). To assess whether N297A induced cytokine release in vivo, naïve
BALB/c mice were injected intraperitoneally (i.p.) with antibodies, and
plasma samples were obtained at 2, 6, and 24 hours post injection. The levels
of cytokines and chemokines were then measured using multiplex analysis. As
expected, WT strongly induced the release of many cytokines and chemokines
in the blood by the 2 hour time point. By 6 hours, levels of most cytokines had
declined but were still higher than baseline. By comparison, N297A-treated
mice had greatly reduced but still detectable levels of cytokines at 2 hours;
these levels were maintained or increased by 6 hours (Table 1). For example,
N297A induced IL-2, IL-6 and KC in the blood but at 10–40 fold lower levels
than observed with WT mAb. In contrast, at 6 hours, IP-10 levels were similar
between N297A- and WT-treated animals.
The reduced level of cytokines induced by N297A treatment was consis-
tently seen in multiple strains of mice including BALB/c, C57/B6 and
IL-10.NOD deficient mice (data not shown). The induction of cytokines and
chemokines by both versions of the anti-murine CD3mAbs was transient. By
24 hours post-injection, the cytokine/chemokine levels returned to base line
(i.e., levels observed in control mAb treated mice; data not shown). Interest-
ingly, there was no additional cytokine release observed when the mice were
treated with a second dose of N297A. This phenomenom was also observed in
human patients upon treatment with a second dose of Fc-modified anti-
human CD3 mAb. N297A, like the Fc-modified anti-human CD3 mAbs, there-
fore induced a reduced level of cytokine release in vivo compared to WT after
initial antibody treatment.
Figure 3: N297A caused a rapid and transient disappearance of blood lymphocytes. (A) C57/
B6 mice were injected i.v. with 10 μg of N297A (), WT () or NCNS1 (✧) mAb. Blood samples
from 5 mice per group were collected in EDTA coated tubes at indicated time points for total
lymphocyte counts. (B) Different dose levels of N297A (10 μg, black bars, or 1 μg, white bars)
or NCNS-1 (dotted bars) were injected i.v. into naïve C57/B6 mice at day 0 (n=5). The mice
were bled at the indicated time point, and CD4+ T cells were quantified by flow cytometry
using TruCOUNT reagents; counts per μl are shown. An unpaired two-tailed t-test was used for
statistical analysis. *p=0.0002 for N297A (10 μg) vs. NCNS-1; # p=0.019 for N297A (1 μg) vs.
NCNS-1 at day 1. The differences at other time points were not statistically significant.
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N297A Preferentially Modulates Activated T Cells in vivo
In order to better understand the biological relevance of N297A-induced
apoptosis in activated but not resting T cells in vitro, we activated OVA Ag
specific T cells from DO11.10 transgenic mice for an adoptive transfer study.
CD4+ T cells from DO11.10 mice were activated in culture with OVA peptide
and transferred into naïve BALB/c mice. One day after the cells were
transferred, the mice were dosed i.v. with 10 μg of mAb. Mice were sacrificed
the next day, and organs were harvested for analysis. Activated DO11.10 T
cells were identified using the KJ1–26 antibody which recognizes the specific
TCR expressed by these cells.
When animals were treated with N297A or WT mAb, both host and donor
populations of T cells disappeared from the blood (as has been consistently
observed with anti-CD3 mAbs). However, there was a clear difference between
the resting host T cells and activated donor T cells in the secondary lymphoid
organs. Thus, 80 to 90% of OVA-activated T cells were eliminated in the
spleens of N297A- and WT-treated mice compared to the negative control
group (Figure 4A, p < 0.0001 for NCNS-1 vs. N297A or WT). Meanwhile, there
was less effect of these antibodies on the host T cells in the spleen (Figure 4B;
p > 0.01 for NCNS-1 vs. N297A or WT). Similar results were observed in the
lymph nodes where N297A and WT treatment led to a reduction of over 80% of
activated OVA-specific T cells (Figure 4C) but only about 30% of host T cells
Table 1: N297A treatment induces reduced but detectable levels of cytokines and 
chemokines compared with WT.
2 hours 6 hours
mIgG1 WT N297A mIgG1 WT N297A
IL-1α 38 399 67 49 1358 715
IL-2 4 4678 118 4 740 168
IL-4 0 1182 11 0 15 3
IL-5 13 102 33 18 1135 508
IL-6 38 7776 425 78 998 532
IL-10 24 348 46 16 695 74
IL-12 19 55 21 14 1172 67
IL-13 45 461 51 41 181 141
IFNγ 2 740 6 1 1788 8
TNFα 10 328 37 9 115 67
G-CSF 275 4533 824 296 16506 9999
GM-CSF 8 898 32 0 76 83
IP-10 442 2571 1196 145 1069 1302
KC 22 4173 399 15 656 556
MCP-1 19 6546 175 14 2626 1129
MIP-1α 367 1437 116 74 277 324
Units are pg/ml.
Five BALB/c mice per group were injected i.p. with indicated antibody and bled after 2 or 6
hours for analysis.86 D. T. Chao et al.
(Figure 4D). These data demonstrate that N297A differentially affected
activated T cells compared to resting T cells in vivo.
Efficacy of N297A in an Adoptive Transfer Model of IBD
Next, we examined the therapeutic potential of N297A in a murine model
of colitis. The IL-10 KO transfer model is characterized by a loss of body
weight starting approximately three weeks after transfer of the IL-10-deficient
CD4+ T cells into NOD/scid recipients. As the disease progresses, these mice
exhibit signs of ill-health including ruffled coats, lethargic appearance, loose
stools and significant body weight loss. Histological evaluation of colons
showed that while the mice that did not receive any IL-10 deficient T cells had
normal colons (Figure 5B), animals that did receive cells had significant
Figure 4: Anti-CD3 mAbs preferentially modulate activated T cells in vivo. Spleen cells from
DO11.10 TCR transgenic mice were activated in vitro for 72 hours with OVA peptide prior to
transfer to BALB/c mice. 24 hours after cell transfer, mice were dosed with 10 μg antibody i.v.
(n=5 per group), and then sacrificed 18 hours after antibody treatment. Spleen and peripheral
lymph nodes were harvested for analysis. Levels of pre-activated CD4+ donor cells (KJ1–26+)
from spleen (A) or lymph node (C) were greatly reduced by treatment with both anti-CD3
mAbs. Levels of host CD4+ cells (KJ1–26-) showed little change in the spleen (B) or a moderate
decrease in lymph node (D) following treatment of N297A (), NCNS-1 (✧) and WT () mAb.
Mice that did not receive any OVA-activated cells (No cells ) were used as control.
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inflammation of the colon with lymphocyte infiltration, epithelial hyperplasia,
loss of epithelial integrity, and loss of goblet cells; this was apparent at 2 to 3
weeks post cell transfer (Figure 5C).
Antibody treatment was initiated in this IL-10 KO transfer model at the
onset of disease symptoms with animals receiving total of 6 doses (10 μg per
dose). Reduction of blood CD4+ T cells in the diseased mice was observed after
the first dose of N297A (data not shown). While control mice that did not
undergo the cell transfer procedure continued to gain weight, the mice that
received IL-10 deficient CD4+ T cells started to show signs of disease and body
weight loss. Treatment with N297A resulted in significantly less weight loss,
and animals did not show the ruffled fur and hunched posture that was
observed in mice treated with NCNS-1 (Figure 5A).
Figure 5: N297A treatment slowed bodyweight loss in the IL-10-deficient adoptive transfer IBD
model. CD4+ T cells from IL-10 deficient mice were purified and transferred into NOD/scid
mice to induce IBD. The antibody treatments were started at disease onset when the mice
started losing body weight. (A) Mice were treated i.v. with 10 μg of N297A (n=9, ) or NCNS-1
(n=9, ✧) 2 to 3 times a week for a total of six doses starting at day 20. No cell control group (❍)
did not receive any T cells and thus continued to grow and gain body weight (n=6). Percent
change in body weight (BW) was calculated by subtracting body weight on day of measure-
ment from ody weight on day 0 and divided by the initial body weight. Statistical significance
was assessed at each time point using an unpaired, two-tailed t-test to derive the p values
between N297A and NCNS-1 groups (*p < 0.05). (B-D) Representative histological images of
the IBD study. (B) Normal colon of control mice that did not receive T cells. Colons of IBD mice
that were treated with 10 μg of NCNS-1 (C) or N297A (D). The colons were harvested at the
end of study and stained with H/E for morphology. The slides were reviewed by a certified
pathologist. Severe inflammation and crypts filled with neutrophils were observed (arrows) in
the colons of most NCNS-1 treated mice.
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Although the difference in body weight was not large, animals in the
N297A treated group had more stabilized body weights compared with control
treated animals and the data was consistent in three separate studies (group
size = 9 to 10 in each study). Therefore, N297A treatment appeared to slow
down disease progression and was able to reverse the body weight loss in this
murine IBD model.
Histological sections of these colons were also analyzed by a certified vet-
erinary pathologist in a blinded fashion for the study. Although there was
large animal-to-animal variation of the histological analysis of the colon,
many colons from NCNS-1 treated mice had severe inflammation, hyperplasia
and presence of crypts with infiltration of neutrophils, whereas colons from
some of the N297A treated mice had less lymphoid infiltration and more
intact goblet cells in their colons (Figure 5D).
DISCUSSION
In the past decade, several anti-human CD3 mAbs have been engineered with
the aim of reducing the side-effects observed with the original murine anti-
CD3 therapeutic, OKT3 (Carpenter et al., 2002; Jacobsohn, 2002; Keymeulen
et al., 2005; Trajkovic, 2002). These next generation anti-CD3 mAbs have
been modified in two main ways. First, they were humanized to reduce human
anti-mouse antibody (HAMA) responses. Second, they have been modified in
the Fc region to diminish the antibody interaction with Fc receptors.
With OKT3, crosslinking of the antibody via interactions with FcRs on
leukocytes was responsible, at least in part, for the potent stimulatory effects
of the antibody that resulted in a high level of cytokine release. The Fc modifi-
cations in the next generation anti-CD3 mAbs result in a reduced mitogenic
potential and abrogated cytokine release.
These modified anti-CD3 mAbs are being evaluated in a number of
autoimmune disease settings. However, their lack of cross-reactivity to CD3 in
lower species has limited mechanistic studies of these antibodies in preclinical
animal models.
To address this issue, we engineered an anti-mouse CD3 mAb to exhibit
many of the in vitro and in vivo characteristics of the anti-human CD3 mAb
visilizumab. We first chimerized the hamster anti-mouse CD3 mAb 145.2C11
to a mouse IgG1 backbone and then introduced a mutation that effectively
abrogated interactions with FcγRs. In the present study we demonstrated that
this antibody, termed N297A, had many functional characteristics in common
with visilizumab, including the ability to induce apoptosis in activated but not
resting T cells, the ability to induce the rapid, transient disappearance of leu-
kocytes from the periphery, and reduced binding to FcγRs compared to non-Fc-
modified parental antibodies with a resulting reduction in the levels of cytok-
ines released into the blood stream.Surrogate for Fc-Modified Anti-Human CD3 mAbs 89
In clinical trials with the Fc-modified anti-human CD3 mAbs, mild to
moderate levels of cytokines were detected between 1 to 8 hours post first dose
(Carpenter et al., 2005; Herold et al., 2005; Keymeulen et al., 2005; Targan S,
2005; Vexler and Woo, 2006). Similarly, we demonstrated that cytokines were
significantly reduced but still detectable upon treatment with N297A com-
pared to WT mAb in our study. Previous reports using other “non-mitogenic”
anti-mouse CD3 mAbs had suggested that these mAbs may not induce any
systemic cytokine release (Li et al., 2006; Ochi et al., 2006). However, the time
point that these groups used for the assessment of cytokine release was at 24
hours post-dose. In our study, circulating cytokine levels were back to baseline
at this time point.
In addition, N297A was shown to have therapeutic activity in a murine
colitis model induced by adoptive transfer of IL-10 deficient CD4+ T cells.
IL-10 deficient mice develop spontaneous colitis due to immune imbalance
and lack of negative regulation (Davidson et al., 1996). When cells from
these mice are transferred to NOD/scid recipients, the pathogenic activated
CD4+ T cells infiltrate the colons and cause severe colitis accompanied by
significant body weight loss. N297A treatment at disease onset reversed the
bodyweight loss associated with colitis. In contrast to the well-tolerated
N297A treatment, the WT mAb was poorly tolerated and indeed was toxic to
these diseased animals, with most mice dying within 24 hours of the initial
dose (data not shown).
While N297A bears many characteristics of Fc-modified anti-human CD3
mAbs, one difference in vitro is in the ability of some mAbs to stimulate low
levels of leukocyte proliferation. For example, visilizumab can elicit low levels
of mitogenicity in human PBMCs although a large donor-to-donor variation is
observed (Cole et al., 1997). In contrast, soluble N297A was unable to stimu-
late any detectable proliferation in spleen cells from multiple strains of mice.
The difference could be explained partially by the differential antigen expo-
sure since most naive mice have been exposed to few if any antigens, whereas
all human donors have been exposed to numerous environmental antigens.
Taken together, these data suggest that N297A will be a useful tool to
further our understanding of the mechanism of action of Fc-modified anti-
human CD3 mAbs. Indeed recent work from Bisikriska et al. has suggested
that the induction of regulatory T cells may be one important mechanism by
which Fc-modified anti-human CD3 mAbs exert their therapeutic benefit
(Bisikirska et al., 2005). We were unable to evaluate whether N297A could
induce regulatory T cells in our adoptive transfer model, as the host mice are
immunodeficient and IL-10 may play a role in the T regulatory function
(Endharti et al., 2005; Gangi et al., 2005; Zhang et al., 2004). However, our
in vivo evaluation of N297A in a transgenic mouse system demonstrated
that the Fc-modified anti-CD3 mAbs preferentially impacted activated
T cells while having limited, if any, effect on resting T cell numbers. These90 D. T. Chao et al.
data are consistent with those seen in vitro and suggest that Fcmodified
anti-CD3 mAbs maybe ideally suited for targeting pathogenic “activated” T
cells in vivo.
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